Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · October 20, 2022

Genomic Classification of Patients With HER2+ Breast Cancer Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy

JCO Precision Oncology

 

Additional Info

JCO Precision Oncology
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
JCO Precis Oncol 2022 Sep 01;6(2022)e2200197, PW Whitworth, PD Beitsch, MK Murray, PD Richards, A Mislowsky, CL Dul, JV Pellicane, PL Baron, RL Rahman, LA Lee, BB Dupree, PR Kelemen, AY Ashikari, RJ Budway, C Lopez-Penalver, W Dooley, S Wang, P Dauer, AR Menicucci, EB Yoder, C Finn, LE Blumencranz, W Audeh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading